若生智能
Drug Database
AT

atenolol + bendroflumethiazide (TenBen / Amoretic LD / Amoretic)

✓ Approved

Warner Chilcott PLC · ADRB1 · 小分子

什么是 atenolol + bendroflumethiazide？

atenolol + bendroflumethiazide 是一种小分子，由Warner Chilcott PLC研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名TenBen, Amoretic LD, Amoretic
公司Warner Chilcott PLC
药物类别小分子
分子靶点ADRB1, SLC12A3
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Warner Chilcott PLC

作用机制

分子靶点

atenolol + bendroflumethiazide 作用于 2 个分子靶点：

ADRB1adrenoceptor beta 1 (B1AR, RHR)
SLC12A3solute carrier family 12 member 3 (NCCT, NCC)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

atenolol + bendroflumethiazide 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved
Renal and urinary disordersRenal failure✓ Approved

相关研究文献

PubMedCureus2026-07-27

A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors.

Iqbal Safiah S, Javed Faiza F, Oyibo Samson O SO

Hypercalcemia is commonly caused by hyperparathyroidism and malignancy. Medication-induced hypercalcemia is less common. Tirzepatide is a dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) used to aid weight loss and glycemic control. It is associated with gastrointestinal side effects, but its effect on calcium homeostasis has not been well reported. We report the case of a 75-year-old woman with a history of type 2 diabetes, hypertension, obesity, chronic kidney disease, and post-surgical hypothyroidism and hypoparathyroidism, who presented with severe symptomatic hypercalcemia one month after starting tirzepatide while taking bendroflumethiazide, calcium carbonate, and alfacalcidol. Her serum calcium levels had been in the normal treatment range before the initiation of tirzepatide. All other possible causes of hypercalcemia were ruled out. Her calcium levels returned to normal after intravenous fluid therapy and withholding tirzepatide, bendroflumethiazide, and calcium carbonate. This case highlights the potential occurrence of severe hypercalcemia during the concurrent use of tirzepatide with bendroflumethiazide, a calcium supplement, and vitamin D in the context of chronic kidney disease. With the increasing use of tirzepatide, healthcare workers need to be mindful of the interaction between tirzepatide and these potential risk factors. While further research is required, we suggest serum calcium monitoring during similar clinical scenarios.

PMID 42504310
阅读全文 →
PubMedPediatric dermatology2026-07-24

A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations.

Fason Claire C, Jafari Alexander J AJ, Hebert Adelaide A AA

Dermatologists play a central role in the diagnosis and medical management of vascular anomalies. Currently, vascular anomalies are categorized into vascular tumors and vascular malformations. The latest designations for the numerous types of vascular lesions are delineated in the International Society for the Study of Vascular Anomalies website (www.issva.org). The arenas for the therapy for hemangiomas, the most common vascular tumor, have been studied extensively and have been recognized as standard of care by the Society for Pediatric Dermatology, the American Academy of Dermatology and the American Academy of Pediatrics. Options for hemangioma treatment include systemic beta-blockers such as propranolol, atenolol, and nadolol, and the topical beta-blocker timolol. Vascular malformations and overgrowth syndromes encompass a separate set of treatment regimens. Recent pharmacological and technological advances in the medical management of vascular anomalies have decreased the need for surgery in many patients while also leading to improved outcomes and quality of life. This review will guide the dermatologist through the current medical treatment landscape for vascular malformations.

PMID 42492908
阅读全文 →
PubMedEuropean journal of pediatrics2026-07-21

Efficacy and safety of interventions for infantile hemangioma compared with oral propranolol: an updated systematic review and bayesian network meta-analysis.

Li Caihong C, Yang Liehao L, Pan Lingfeng L

The purpose of the study is to compare the efficacy and safety of available interventions for infantile hemangioma against oral propranolol and to evaluate the certainty of the comparative evidence. We conducted a Bayesian network meta-analysis in accordance with PRISMA-NMA guidelines and systematically searched PubMed, Embase, the Cochrane Library, and CNKI from January 2008 to June 2026. A random-effects consistency model was fitted using the BUGSnet package. Evidence certainty was assessed using the CINeMA framework, and risk of bias was evaluated using the revised Cochrane RoB 2 tool. Thirty randomized controlled trials (RCTs) including 2,639 patients across nine treatment nodes were included in the efficacy analysis, and 12 RCTs involving 1,143 patients across eight nodes were included in the safety analysis. Using oral propranolol as the reference treatment, no active intervention demonstrated statistically significant superiority in efficacy, whereas placebo was significantly inferior. Corticosteroids were the only intervention associated with substantially higher adverse event rates, whereas atenolol showed a trend toward fewer adverse events. By anchoring all comparisons to oral propranolol and integrating CINeMA certainty assessments with inconsistency testing, these findings are consistent with the continued role of oral propranolol as the reference systemic treatment for infantile hemangioma. For patients intolerant to propranolol, atenolol may represent a reasonable alternative. By anchoring all comparisons to oral propranolol and integrating CINeMA certainty assessments with inconsistency testing, these findings are consistent with the continued role of oral propranolol as the reference systemic treatment for infantile hemangioma. For patients intolerant to propranolol, atenolol may represent a reasonable alternative. • Oral propranolol is the established first-line systemic therapy for infantile hemangioma. • Previous network meta-analyses have reported treatment rankings, but the clinical meaning of these rankings relative to oral propranolol remains uncertain. • Despite favorable point estimates for combination therapy and nadolol, this benchmark-anchored analysis found no included active intervention statistically superior to oral propranolol. • Certainty assessment showed that treatment rankings were limited by heterogeneity, inconsistency, risk of bias, and imprecision; atenolol had the largest body of direct comparative evidence among the alternatives.

PMID 42479211
阅读全文 →
PubMedAdvanced genetics (Hoboken, N.J.)2026-07-17

Genetic Bone Diseases: A Scoping Review of Pathology, Symptoms, Diagnosis, Treatment, and New Horizons.

Jones Colin C, Jayasuriya Ambalangodage C AC

Genetic bone diseases are a rare group of afflictions suffered by the general population. However, their rarity should not diminish research efforts to help patients understand and treat their diseases. This review summarizes the pathology, symptoms, diagnosis, and treatment insight into six well-known genetic bone diseases. Only six bone diseases are included due to the relatively low prevalence of them as whole limiting our scope to ensure accurate information and attention is provided for each disease individually. A literature search of PubMed is conducted, including studies published within the past five years (January 2020-December 2025). Thirty-six studies met inclusion criteria, and no significant risk of bias is identified among the selected articles. Study findings are synthesized into disease overview, clinical and radiographic features, and diagnostic and treatment approaches. Actively developing or novel therapies relevant to each disease are also included. These treatments include: fresolimumab for osteogenesis imperfecta, small interfering ribonucleic acid (RNA) therapy for Osteopetrosis, denosumab for Paget's disease of bone, vosoritide/recifercept/infigratinib for achondroplasia, mesenchymal stem cell therapy for craniosynostosis, and combination losartan and atenolol therapy for Marfan syndrome. These treatments are generally more recently acknowledged in literature and are either actively undergoing research or require further research to determine their efficacy.

PMID 42466325
阅读全文 →
PubMedJACC. Clinical electrophysiology2026-07-10

Beta-Blockers and Exercise Performance in Children with Long QT Syndrome.

Webster Gregory G, Gill Nathan N, Carberry Thomas T, Chandler Stephanie F SF et al.

Young people taking beta-blockers for long QT syndrome (LQTS) have concerns about exercise performance. This study sought to determine whether objective measures of cardiopulmonary fitness are influenced by beta-blocker dose in LQTS. In a retrospective chart review of treadmill cardiopulmonary exercise tests (CPETs), we measured peak oxygen consumption (Vo2), respiratory exchange ratio (RER), blood pressure, and percent predicted heart rate at peak exertion (%PHR), each analyzed with a linear mixed-effects model. We analyzed nadolol data (noncardioselective) as our primary analysis, then analyzed a validation cohort of atenolol data (cardioselective). We evaluated 220 CPETs in 93 patients with LQTS. The mean age at first CPET was 12 ± 3.9 years. In multivariable analysis, %PHR decreased by 13% for every 1 mg/kg/d increase in beta-blocker dose, demonstrating physiologic beta-blocker effects. However, we identified no correlation between nadolol dose and measures of cardiopulmonary fitness. Neither peak Vo2 nor peak RER was correlated with nadolol dose. Only mild blood pressure changes were observed (<9 mm Hg decrease at peak exertion per 1 mg/kg increase in nadolol dose). Increased atenolol dose was also associated with stable peak Vo2 and peak RER. In children with LQTS, we did not observe any relationship between higher nadolol doses and objective measures of effort (peak RER) or cardiopulmonary fitness (peak Vo2), despite a linear dose-response between nadolol dose and %PHR. These results suggest that treatment with nadolol for LQTS does not affect most patients' peak exercise performance. These data were validated in patients from an earlier era who had been prescribed atenolol.

PMID 42429723
阅读全文 →
PubMedWater research2026-07-09

Metagenomic insights into microbial drivers of organic micropollutant removal in wastewater-impacted riverbank filtration.

Zhai Yujia Y, Wang Xun X, Deng Xuhan X, Li Xiaoming X et al.

Organic micropollutants (OMPs) in wastewater treatment plant (WWTP) effluent pose persistent risks to aquatic ecosystems and drinking water sources. Riverbank filtration (RBF) is a nature-based treatment process, yet the compartment-specific roles of riverbed sediment and downstream soil in OMP attenuation remain poorly resolved under wastewater-impacted conditions. Here, we combined targeted chemical analysis, OMP property compilation, shotgun metagenomics, EnviPath-based biotransformation annotation, and exploratory network analysis to investigate OMP attenuation in a laboratory-scale RBF system treating real WWTP effluent for 10 months. Nineteen OMPs were monitored along a sequential sediment-soil filtration pathway. Sediment preferentially attenuated hydrophilic or charged compounds, including lidocaine, amantadine, and sotalol, whereas soil contributed more strongly to the attenuation of naproxen, atenolol, and losartan. Metagenomic profiling revealed distinct microbial communities and functional gene repertoires between sediment and soil after long-term operation. Sediment harbored higher relative abundances of genes associated with oxidative xenobiotic transformation, including cytochrome P450-related enzymes, demethylases, dehydrogenases, oxidases, and aromatic compound degradation pathways. An exploratory Spearman network further identified associations among microbial genera, EnviPath-annotated candidate biotransformation genes, and OMP removal rates, including 17 KO-OMP links supported by both correlation and pathway annotation. These findings indicate that sediment and soil develop complementary microbial functional potentials that may support compound-specific OMP attenuation. This study provides a mechanistic basis for optimizing sediment-soil configurations in wastewater-impacted RBF systems and for improving nature-based barriers against diverse OMP mixtures.

PMID 42418982
阅读全文 →

注册免费账户还可查看另外 8166 篇文献

免费注册查看全部文献 →

了解更多atenolol + bendroflumethiazide